About the Company
We do not have any company description for Inmune Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Inmune Bio, Inc.
INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and ...
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio Inc. to Host Conference Call on Phase 2 MINDFuL Trial ...
INmune Bio Inc. will hold a conference call on June 30, 2025, at 8:00 AM EDT to discuss top line data from its Phase 2 MINDFuL trial in early Alzheimer's Disease.
INmune Bio, Inc. Announces First Patient Treated with NK cell priming ...
INmune Bio Contact:David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact:Chuck PadalaLifeSci Advisors (646) 627-8390 chuck@lifesciadvisors.com Source: INmune Bio, Inc.
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ETCompany ParticipantsRJ Tesi - Chief Executive OfficerDavid Moss - ...
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
INmune Bio Inc. Announces First Quarter 2025 Results and Provides ...
About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b ...
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering ...
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio's second quarter 2025 financial results. Presenting on today's call are David Moss, ...
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript
INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.00048, expectations were $-0.39. Operator: Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call.
Similar Companies
Loading the latest forecasts...